Recent News

• 02.02.2026 - IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
• 01.30.2026 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 01.11.2026 - IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
• 12.11.2025 - IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
• 12.10.2025 - IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
• 12.01.2025 - IDEAYA Biosciences Announces IND Clearance for IDE034, a Potential First-in-Class Bispecific B7H3/PTK7 TOP1 ADC Targeting Multiple Solid Tumor Types
• 11.28.2025 - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 11.24.2025 - IDEAYA Biosciences to Participate in Upcoming December 2025 Investor Relations Events
• 11.04.2025 - IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update

Recent Filings

• 01.12.2026 - 8-K Current report
• 01.12.2026 - 8-K Current report
• 01.12.2026 - EX-99.1 EX-99.1
• 01.08.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.12.2025 - 8-K Current report
• 12.05.2025 - 8-K Current report
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.04.2025 - 8-K Current report
• 11.04.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.04.2025 - EX-99.1 EX-99.1